

October 24, 2022



## Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance and presentation of six posters featuring Nyxol<sup>®</sup> and APX3330 at the [American Academy of Optometry \(AAOPT\) 2022 Annual Meeting](#) being held October 26-29, 2022 in San Diego, CA.

### **AAOPT 2022: San Diego Convention Center**

Title: **Safety and Tolerability of Phentolamine Ophthalmic Solution for Reversal of Mydriasis in Two MIRA Phase 3 Trials**

Poster #: 260, Exhibit Hall H

Date/Time: Thursday, October 27, 2022, 4:30 PM – 6:30 PM PT

Presenter: Justin Schweitzer, OD

Title: **Masked Safety of Oral Drug Candidate APX3330 for the Treatment of Diabetic Retinopathy in an Ongoing ZETA-1 Phase 2b Clinical Trial**

Poster #: 200, Exhibit Hall H

Date/Time: Thursday, October 27, 2022, 4:30 PM – 6:30 PM PT

Presenter: Doug Devries, OD

Title: **Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal MIRA Phase 3 Trials**

Poster #: 188, Exhibit Hall H

Date/Time: Friday, October 28, 2022, 1:00 PM – 3:00 PM PT

Presenter: Leslie O'Dell, OD

Title: **MIRA-4, Clinical Trial Evaluating the Safety and Efficacy of Phentolamine Ophthalmic Solution for Reversal of Pharmacologically Induced Mydriasis in Pediatric Subjects Aged 3-11 Years**

Poster #: 187, Exhibit Hall H

Date/Time: Friday, October 28, 2022, 1:00 PM – 3:00 PM PT

Presenter: Shane Foster, OD

Title: **Phentolamine Alone and in Combination with Low Dose Pilocarpine Improves Near Vision in Presbyopic Subjects in the VEGA-1 Phase 2 Trial**

Poster #: 186, Exhibit Hall H

Date/Time: Friday, October 28, 2022, 1:00 PM – 3:00 PM PT

Presenter: Mitch Ibach, OD

Title: **LYNX-1: A Pivotal Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbance**

Poster #: 185, Exhibit Hall H

Date/Time: Friday, October 28, 2022, 1:00 PM – 3:00 PM PT

Presenter: Shane Kannarr, OD

## About Ocuphire Pharma

Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders. For more information about Ocuphire's clinical trials, visit <https://www.ocuphire.com/clinical-trials>.

## Ocuphire Contacts

Mina Sooch, President & CEO  
Ocuphire Pharma, Inc.  
[ir@ocuphire.com](mailto:ir@ocuphire.com)

Corey Davis, Ph.D.  
LifeSci Advisors  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

Bret Shapiro  
Core IR  
[brets@coreir.com](mailto:brets@coreir.com)



Source: Ocuphire Pharma